Latest Development Program News

Maronan Metals has completed more than 15,000 metres of a 40,000-metre infill program and is preparing to accelerate work at its Queensland project with a proposed A$20 million placement. The funding remains subject to shareholder approval, while a new chief executive is due to take charge in November.

Brookside Energy is expanding beyond its operated SWISH program with five proposed non-operated horizontal wells across three Oklahoma plays. The estimated US$3.5 million investment is intended to add future production and cash flow without drawing on a new equity issue.

Iondrive received $3.765 million in grant cash during FY2026, including $3.691 million from the Australian Government’s Industry Growth Program. The company has deferred $1.671 million of that funding until further eligible pilot plant expenditure is incurred.

First Graphene reported unaudited first-quarter income of about A$201,000, up 21% year on year, as PureGRAPH moved into new cement, mining, composites and footwear applications. The commercial pipeline expanded, but A$915,000 of operating cash outflow left the company with A$1.831 million and an estimated two quarters of funding at the reported burn rate.

Medallion Metals is moving towards first gold production, with Cosmic Boy processing scheduled to begin this month and initial sales expected in November. At Kundip, the first box-cut blast is complete and underground development remains targeted for December.

Ryman Healthcare’s retirement village resales reached an eight-quarter high in the second quarter, while aged care occupancy climbed to 94%. The operating update also shows new-sales inventory continuing to decline as the company positions for stronger recurring earnings.

Sunshine Metals has extended gold mineralisation at its Sybil project in North Queensland, led by a 4-metre intersection grading 11.11g/t gold at Francis Creek. The company plans a further 2,600 metres of drilling from mid-October across existing and untested targets.

Neurotech International has moved NTI164 into a registration-enabling Phase III autism trial, but its annual report carries a material going-concern warning. The company says post-year-end debt and equity funding should support the program through topline data, subject to execution and completion.

First Graphene has signed a three-year agreement with Turkish manufacturer Aeropreg to develop and potentially commercialise PureGRAPH-enhanced carbon fibre prepreg. The partnership offers a clearer route into aerospace, defence and automotive supply chains, but commercial launch remains dependent on trial results.

Stonehorse Energy returned to profit in FY2026 as Canadian production and oil exposure lifted revenue, while the company sold its US assets after year-end. The next test is whether Drumheller can convert production growth into sustainable cash flow while carrying new debt.

ClearVue Technologies reported just A$108,484 of FY2026 revenue against an A$11.86 million loss, while consuming A$8.69 million in operating cash. The solar-glazing developer says certifications, international partners and an 80-project pipeline have strengthened its platform, but the next test is converting those assets into cash revenue.

Clarity Pharmaceuticals is approaching pivotal Phase III readouts for its prostate cancer imaging agent, backed by AUD178.3 million in liquid assets. The radiopharmaceutical developer remains deeply loss-making, but expanded manufacturing capacity and early clinical signals are pulling its commercial ambitions into sharper focus.